To kick things off, we'll set the stage on what defines non-muscle invasive bladder cancer and how we triage patient ...

Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared with placebo –– ...

The perioperative enfortumab vedotin plus pembrolizumab (EV-P) substantially increased the frequency of adverse events (AEs), ...

Results presented by AstraZeneca from its phase 3 trial of Imfinzi in patients with high-risk, non-muscle invasive bladder ...

This is the first meta-analysis comparing the overall survival of patients with limited-stage small cell bladder cancer who underwent radical surgery with platinum-based perioperative chemotherapy vs ...

Enfortumab vedotin and pembrolizumab with surgery significantly improve outcomes in cisplatin-ineligible MIBC patients, ...

The BladderPath trial indicates that mpMRI can expedite MIBC treatment and improve bladder cancer-specific survival compared to traditional TURBT. The study showed a significant improvement in BCSS ...

BERLIN -- Adding durvalumab (Imfinzi) to bacillus Calmette-Guérin (BCG) induction and maintenance therapy significantly ...

To our knowledge, SunRISe-4 shows, for the first time, a benefit of the addition of the localised TAR-200 gemcitabine intravesical system to systemic checkpoint inhibition as neoadjuvant treatment in ...